Ovarian Cancer Immunology and Immunotherapy– 2026
Guest Editor: Chris D. Platsoucas, Ph.D., D.Sc. (h.c.), Professor, Department of Biological Sciences, Old Dominion University, Norfolk, VA, U.S.A.
TOPICS:
● T Cells and Tumor-Infiltrating Lymphocytes (TILs):
o CD8⁺ cytotoxic T cells
o CD4⁺ T cells
o Progenitor stem-like memory T cells
o Clonally expanded T cells and T-cell receptors
● Antigen-Presentation and HLA associations:
o Antigen-presenting cells (dendritic cells and others)
o HLA associations
● Tumor Antigens:
o Tumor-associated antigens
o Tumor-specific antigens. Neoantigens. TP53, RAS
● Tumor Genetics and Variants:
o Genetic and somatic variations of tumor cells
● B cells and Autoantibodies. Cytokines.
● Natural Killer (NK) Cells and Innate Immunity.
● Tumor Microenvironment.
● Immunosuppression:
o Immunosuppressive cells: Tregs, myeloid-derived suppressor cells, tumor-associated macrophages
o Immunosuppressive molecules (IL-10, TGF-β, others)
● Single-cell analysis studies.
● Checkpoint Inhibitors and Immune Modulation:
o PD-1, PD-L1, and other checkpoints
● Immunotherapy Approaches:
o Adoptive cell therapies (TILs, CARs)
o Immune response modulators
o Animal models of ovarian cancer
Deadline for article(s) submission: February 5, 2026.
The special issue is scheduled for publication in April 2026.
Manuscripts (reviews and original experimental or clinical research articles) should follow the Instructions for Authors of Anticancer Research and should be submitted for publication through our new online submission system: www.iiar-submissions.com